Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Clinical Immunology

Protecting the Immune System

At a Glance

The main protection for a child with agammaglobulinemia is long-term antibody replacement, given through a vein or under the skin, combined with vaccine safety, infection prevention, and urgent evaluation of fever or breathing problems.

The ‘agammaglobulinemia’ part of this syndrome is a serious but manageable immune deficiency. It happens because of a failure in how your child’s body makes B-cells [1]. B-cells are specialized white blood cells that produce immunoglobulins (also called antibodies) [2].

In this syndrome, the B-cells stop developing very early in the process. Because these are never fully built, your child’s body cannot produce the antibodies needed to recognize and fight off common germs [1][3]. Without treatment, this leads to frequent and potentially severe infections.

The Standard of Care: Antibody Replacement

When antibody production is profoundly deficient, the treatment is usually long-term Immunoglobulin Replacement Therapy (IgRT) [4][5]. This provides antibodies from healthy donors to help protect your child from invasive bacterial infections like pneumonia and sepsis [6].

There are two main ways this medicine is given:

  • Intravenous (IVIg): This is an infusion directly into a vein, often performed in a hospital or clinic every 3 to 4 weeks [7][8].
  • Subcutaneous (SCIg): This involves smaller doses delivered just under the skin using a tiny needle. This is often done at home, once or twice a week [9][10].

The dose, interval, route, and target IgG levels are individualized based on your child’s weight, infection history, laboratory results, and skin health [9]. Common infusion reactions include headache, fatigue, or mild fever. If your child develops severe headache/neck stiffness, difficulty breathing, or a new rash during or after an infusion, follow your specific product instructions or seek emergency care immediately.

Infection Prevention and Safety

While antibody replacement is powerful, it provides mostly IgG. It does not replace other types like IgA or IgM, which protect the mucous membranes of the lungs and gut. It substantially reduces but does not eliminate infections [8][11]. Your medical team may recommend additional layers of protection:

  • Prophylactic Antibiotics: Some children take a daily low-dose antibiotic to prevent bacteria from gaining a foothold, especially if infections persist despite immunoglobulin therapy [12][13][14].
  • Vaccine Safety: Do not change the vaccine schedule without speaking to the immunologist. Children with this syndrome generally must avoid live vaccines (such as MMR, varicella, oral rotavirus, live-attenuated influenza, or the BCG bacteria vaccine), as the live organism could cause actual disease [15][16]. ‘Inactivated’ (killed) vaccines are generally safe, though they may produce a weaker response [17][18].
  • Household Protection: Household contacts usually need to stay up to date on their own vaccines to create a protective buffer, but ask your immunologist if any special precautions are needed when family members receive live vaccines [19].

Red Flags: When to Seek Emergency Care

Because your child’s immune system is compromised, a small infection can turn serious very quickly. If you notice any of the following, seek immediate medical attention:

  • Fever: Any temperature of at least 100.4°F (38.0°C) or as specifically directed by your individualized fever plan [20]. Do not wait for a second reading.
  • Respiratory Distress: Fast breathing, grunting, pauses in breathing, or the skin pulling in around the ribs (retractions) [21].
  • Change in Alertness: Extreme sleepiness, difficulty waking up, or unusual irritability [20].
  • Dehydration: Severe vomiting or diarrhea, or no wet diapers [22].
  • Skin Changes: Sudden redness, warmth, or pus-filled blisters, especially with fever [23][24].

Create a ‘Carry With You’ Emergency Box Plan
Work with your immunologist to write a concrete emergency action plan. It should include the diagnosis description, the immunologist’s and pharmacy’s emergency contact numbers, current immunoglobulin product and dose, allergies, vaccine restrictions, your fever threshold, and a note to emergency staff that prompt clinical assessment (which may include early ‘empiric’ IV antibiotics) is necessary [25][22].

Common questions in this guide

What treatment supplies the antibodies a child is missing?
Long-term immunoglobulin replacement therapy supplies antibodies from healthy donors. It can be given through a vein, often every 3 to 4 weeks, or under the skin, often once or twice a week; the immunologist chooses the plan based on the child's needs.
How do doctors choose between IVIg and SCIg?
Both routes can provide antibody replacement, but neither is automatically best for every child. The choice, dose, and schedule depend on weight, infection history, laboratory results, skin health, and what the family can manage safely.
Which vaccines should a child with this syndrome avoid?
Children with this severe antibody deficiency generally should not receive live vaccines, including MMR, chickenpox, oral rotavirus, live-attenuated influenza, or BCG, unless their immunologist gives specific instructions. Inactivated vaccines are generally safer but may produce a weaker response, so do not change the schedule without medical advice.
Could my child need antibiotics even while receiving antibody replacement?
Possibly. An immunologist may recommend a daily preventive antibiotic when infections continue despite immunoglobulin therapy; this decision depends on the child's infection history and medical risks.
When should I seek emergency care for a child with agammaglobulinemia?
Follow the child's individualized fever plan, but a temperature of at least 100.4°F (38.0°C) should prompt immediate medical attention unless the care team has given different instructions. Seek urgent care for breathing trouble, difficulty waking, severe vomiting or diarrhea with reduced urination, or rapidly worsening redness, warmth, or pus-filled skin lesions.
Does antibody replacement prevent every infection?
No. It provides mostly IgG antibodies and substantially lowers the risk of serious bacterial infections, but it does not replace IgA or IgM and cannot eliminate all infections.

Get notified when new evidence is published on Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (25)
  1. 1

    A newly recognized, likely autosomal recessive syndrome comprising agammaglobulinemia, microcephaly, craniosynostosis, severe dermatitis, and other features.

    Crow YJ, Goodship JA, Wright C, et al.

    American journal of medical genetics. Part A 2006; (140(11)):1131-5 doi:10.1002/ajmg.a.31275.

    PMID: 16691627
  2. 2

    Agammaglobulinemia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management.

    Pashangzadeh S, Yazdani R, Nazari F, et al.

    Endocrine, metabolic & immune disorders drug targets 2020; (20(9)):1434-1447 doi:10.2174/1871530320666200508114349.

    PMID: 32384040
  3. 3

    Autosomal recessive agammaglobulinemia due to defect in μ heavy chain caused by a novel mutation in the IGHM gene.

    Silva P, Justicia A, Regueiro A, et al.

    Genes and immunity 2017; (18(3)):197-199 doi:10.1038/gene.2017.14.

    PMID: 28769069
  4. 4

    Revisiting X-linked agammaglobulinemia.

    Kanegane H, Tanita K, Nishimura M, et al.

    Journal of human immunity 2025; (1(1)):e20250020 doi:10.70962/jhi.20250020.

    PMID: 42170232
  5. 5

    X-linked agammaglobulinemia: ınvestigation of clinical and laboratory findings, novel gene mutations and prevention of ınfective complications in long-term follow-up.

    Yıldırım İ, Topyıldız E, Bilgin RBG, et al.

    American journal of clinical and experimental immunology 2021; (10(1)):37-43.

    PMID: 33815962
  6. 6

    Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections.

    Langereis JD, van der Flier M, de Jonge MI

    Frontiers in immunology 2018; (9()):1925 doi:10.3389/fimmu.2018.01925.

    PMID: 30190722
  7. 7

    Serial Serum Immunoglobulin G (IgG) Trough Levels in Patients with X-linked Agammaglobulinemia on Replacement Therapy with Intravenous Immunoglobulin: Its Correlation with Infections in Indian Children.

    Suri D, Bhattad S, Sharma A, et al.

    Journal of clinical immunology 2017; (37(3)):311-318 doi:10.1007/s10875-017-0379-5.

    PMID: 28321612
  8. 8

    An update on X-Linked agammaglobulinaemia: clinical manifestations and management.

    Shillitoe BMJ, Gennery AR

    Current opinion in allergy and clinical immunology 2019; (19(6)):571-577 doi:10.1097/ACI.0000000000000584.

    PMID: 31464718
  9. 9

    Current Spectrum of Infections in Patients with X-Linked Agammaglobulinemia.

    Paccoud O, Mahlaoui N, Moshous D, et al.

    Journal of clinical immunology 2021; (41(6)):1266-1271 doi:10.1007/s10875-021-01043-1.

    PMID: 33880703
  10. 10

    Clinical and laboratory observation on immunoglobulin replacement therapy switching from an intravenous to a subcutaneous route in a Malaysian X-linked agammaglobulinemia patient.

    Adli A, Wahab AA, Abdul Latiff AH, et al.

    The Medical journal of Malaysia 2022; (77(1)):95-97.

    PMID: 35087003
  11. 11

    Evaluation of respiratory complications in patients with X-linked and autosomal recessive agammaglobulinemia.

    Fekrvand S, Yazdani R, Olbrich P, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2020; (31(4)):405-417 doi:10.1111/pai.13228.

    PMID: 32058651
  12. 12

    X-linked Agammaglobulinemia.

    Suri D, Rawat A, Singh S

    Indian journal of pediatrics 2016; (83(4)):331-7 doi:10.1007/s12098-015-2024-8.

    PMID: 26909497
  13. 13

    Specific Antibody Deficiency: Controversies in Diagnosis and Management.

    Perez E, Bonilla FA, Orange JS, Ballow M

    Frontiers in immunology 2017; (8()):586 doi:10.3389/fimmu.2017.00586.

    PMID: 28588580
  14. 14

    Lung Disease in Primary Antibody Deficiencies.

    Schussler E, Beasley MB, Maglione PJ

    The journal of allergy and clinical immunology. In practice 2016; (4(6)):1039-1052 doi:10.1016/j.jaip.2016.08.005.

    PMID: 27836055
  15. 15

    Vaccination in PADs.

    Milito C, Soccodato V, Collalti G, et al.

    Vaccines 2021; (9(6)) doi:10.3390/vaccines9060626.

    PMID: 34207916
  16. 16

    Current status of BCG and OPV vaccination in children with primary immunodeficiency in Chongqing, China.

    Liu Y, Zhang Y, Ning Y, et al.

    Medicine 2025; (104(40)):e44935 doi:10.1097/MD.0000000000044935.

    PMID: 41054950
  17. 17

    Vaccination in Primary Immunodeficiency Disorders.

    Sobh A, Bonilla FA

    The journal of allergy and clinical immunology. In practice 2016; (4(6)):1066-1075 doi:10.1016/j.jaip.2016.09.012.

    PMID: 27836056
  18. 18

    Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency.

    Hanitsch LG, Löbel M, Mieves JF, et al.

    Vaccine 2016; (34(21)):2417-2423 doi:10.1016/j.vaccine.2016.03.091.

    PMID: 27055021
  19. 19

    Influenza Vaccination in Patients with Common Variable Immunodeficiency (CVID).

    Mieves JF, Wittke K, Freitag H, et al.

    Current allergy and asthma reports 2017; (17(11)):78 doi:10.1007/s11882-017-0749-3.

    PMID: 28983790
  20. 20

    Invasive Haemophilus influenzae type b infection in a patient with transient hypogammaglobulinemia of infancy.

    Otaki Y, Ogawa E, Higuchi T, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2021; (27(12)):1756-1759 doi:10.1016/j.jiac.2021.07.023.

    PMID: 34376350
  21. 21

    Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).

    Syed MN, Kutac C, Miller JM, et al.

    Journal of clinical immunology 2022; (42(7)):1545-1552 doi:10.1007/s10875-022-01317-2.

    PMID: 35779201
  22. 22

    Viral infection in primary antibody deficiency syndromes.

    Jones TPW, Buckland M, Breuer J, Lowe DM

    Reviews in medical virology 2019; (29(4)):e2049 doi:10.1002/rmv.2049.

    PMID: 31016825
  23. 23

    The prevalence of allergic manifestations in inborn errors of immunity: a retrospective cohort study.

    Esmaeilzadeh H, Esmaeilbeig M, Askarisarvestani A, et al.

    BMC immunology 2025; (26(1)):73 doi:10.1186/s12865-025-00758-9.

    PMID: 41023596
  24. 24

    Hypogammaglobulinemia in Children with Atopic Dermatitis.

    Karali Z, Karali Y, Senocak Z, Kilic SS

    Children (Basel, Switzerland) 2026; (13(5)) doi:10.3390/children13050696.

    PMID: 42194222
  25. 25

    Secondary antibody deficiency - causes and approach to diagnosis.

    Srivastava S, Wood P

    Clinical medicine (London, England) 2016; (16(6)):571-576 doi:10.7861/clinmedicine.16-6-571.

    PMID: 27927823

This page is for informational purposes only and does not constitute medical advice. Your child's immunologist should tailor antibody treatment, vaccine decisions, and emergency instructions.

Guide contents Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome
Research & Literature
03 Genetics, Genetic Testing, and Overlapping Conditions 05 Craniofacial and Neurological Care